Skip to content
Open access

Interpretable multimodal deep learning for time-resolved survival prediction after hepatocellular carcinoma resection.

Jul 2026 · npj Digital Medicine · 0 citations
Medicine

TL;DR

TEMPO-HCC represents a paradigm shift from static binary classification toward clinically actionable temporal risk prediction, and provides an auditable evidence chain linking macro-scale radiologic phenotypes to micro-scale histopathologic patterns.

Abstract

Hepatocellular carcinoma (HCC) exhibits substantial interpatient heterogeneity, leading to markedly variable outcomes and survival even among patients with similar stages and imaging phenotypes. Mainstream staging systems remain suboptimal, whereas pathology-dependent factors and high-cost genomic assays are neither scalable nor timely for clinical decision-making. Existing algorithms provide coarse risk stratification or static binary predictions, failing to capture the time-varying risk of death. We developed and externally validated TEMPO-HCC, a multimodal deep survival model with hierarchical interpretability, to estimate individualized overall survival risk trajectories after curative-intent resection. We curated a six-center cohort of 1475 patients and integrated multiphasic MRI, postoperative H&E whole-slide images, and perioperative predictors. A discrete-time survival head generated probabilities at 1, 2, 3, and 5 years after surgery. TEMPO-HCC outperformed unimodal models and guideline-based staging systems, achieving C-index of 0.751 and time-dependent AUCs of 0.836, 0.781, 0.812, and 0.680 at 12, 24, 36, and 60 months, respectively, in the external validation cohort. TEMPO-HCC represents a paradigm shift from static binary classification toward clinically actionable temporal risk prediction. Its hierarchical interpretability provides an auditable evidence chain linking macro-scale radiologic phenotypes to micro-scale histopathologic patterns. Importantly, augmenting guideline staging with TEMPO-HCC improved discrimination, enabling personalized postoperative surveillance and risk-adapted clinical management.

Read PDF

Similar papers

Open access Sep 2026

A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma

Background Surgical resection is the standard treatment for stage I lung adenocarcinoma, in most cases without additional systemic adjuvant treatment. A substantial proportion of stage I cases recur, with a 5-year survival rate <50%. Clinical data suggest that adjuvant treatment, including immune checkpoint inhibitor t...

O. Kilim, O. Pipek, Z. Sztupinszki et al. · 0 citations
Open access Sep 2026

Deep learning CT signature for predicting early liver metastases in pancreatic ductal adenocarcinoma

Accurately predicting the risk of early liver metastases (ELM) and identifying patients who are most likely to benefit from neoadjuvant therapy (NAT) are critical for pancreatic ductal adenocarcinoma (PDAC). Here, we develop a Mamba-based predictive model that integrates imaging features from both the primary pancreati...

Ben Zhao, Zhi-Fang Gong, W. Xiao et al. · 0 citations
Open access Sep 2026

Deep Learning-Based Multi-Cancer Analysis for Predicting Disease-Free Survival Across Multiple Cancer Types

The deep learning-based multi-cancer disease-free survival model performed robustly across cancer subtypes, with the nomogram improving risk stratification, particularly for stage I malignancies, complementing existing staging.

Si-Teng Chen, En-Cheng Zhang, Fu-Kang Sun et al. · 0 citations
Open access Oct 2026

HepaKineticNet: Deep Learning of CT-Derived Intratumoral Heterogeneity for Overall Survival Prediction in BCLC Stage B-C Hepatocellular Carcinoma Treated with Locoregional Therapy Plus First-Line TKI and Anti–PD-1 Therapy

Purpose To develop HepaKineticNet, a deep learning framework that models inter-phase kinetic dynamics on multi-phase contrast-enhanced CT (CECT) to generate intratumoral heterogeneity (ITH) maps, and to assess in an independent external cohort whether a clinical–radiomics fusion model improves overall survival (OS) pre...

Jin-Peng Li, Wen-Zhe Bu, Xiaotian Hanming et al. · 0 citations
Sep 2026

Breast Cancer Recurrence Status Assessment in 5 Years Using Multimodal Integrated Learning: A Feasibility Study.

The findings underscore the potential of the proposed multimodal deep learning framework to provide accessible, accurate, and generalizable recurrence risk prediction using routinely available clinical data, potentially supporting more informed treatment decisions and personalized post-treatment monitoring in real-worl...

R. Chang, Hsiang-Wei Huang, Szu-Yen Kuo et al. · 0 citations

Explainable AI for analyzing cancer outcomes using large-scale genome sequencing data

A multi-tier, explainable AI framework designed to risk-stratify patients and predict overall survival using clinical and genomic covariates is developed and demonstrates that explainable machine learning models can robustly predict survivability and highlight actionable features for oncology dashboards.

P. Nalela · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.